FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeremy Braybrooke

Research Profile

Concepts & Ideas

Chemicals & Drugs

Procedures

Disorders

Co-author Network

Publications

TOP 3
K Manley; Jeremy P Braybrooke; K Edey; J Murdoch
Hormone replacement therapy after endometrial cancer.
Chun Sing Louis Tsui; Hai-Dong Liang; Michael Halliwell; Mike Shere; Jeremy P Braybrooke; Elisabeth Whipp; Peter N T Wells
Coherent ultrasonic Doppler tomography.
S R Muthuramalingam; T Perren; Susan Wilner; A D Blann; Jeremy P Braybrooke; Cheng Han; A Jenkins; K Kaur; Srinivasan Madhusudan; Trivadi Ganesan
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeremy Braybrooke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: K Manley; Jeremy P Braybrooke; K Edey; J Murdoch
Hormone replacement therapy after endometrial cancer.
Menopause international 2012;18(4):134-8.
2011: Chun Sing Louis Tsui; Hai-Dong Liang; Michael Halliwell; Mike Shere; Jeremy P Braybrooke; Elisabeth Whipp; Peter N T Wells
Coherent ultrasonic Doppler tomography.
Ultrasound in medicine & biology 2011;37(4):642-50.
2011: S R Muthuramalingam; T Perren; Susan Wilner; A D Blann; Jeremy P Braybrooke; Cheng Han; A Jenkins; K Kaur; Srinivasan Madhusudan; Trivadi Ganesan
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
European journal of gynaecological oncology 2011;32(3):253-8.
2008: David N Church; Ramayana Modgil; Sam Guglani; Amit Bahl; Kirsten Hopkins; Jeremy P Braybrooke; Peter Blair; Chris G A Price
Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
American journal of clinical oncology 2008;31(3):250-4.
2005: Srinivasan Madhusudan; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances R Balkwill; Trivadi Ganesan
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5950-9.
2005: Nicola C Levitt; David J Propper; Srinivasan Madhusudan; Jeremy P Braybrooke; C Echeta; Robert te Poele; Sally L Davies; Elizabeth Flanagan; Ian D Hickson; Simon P Joel; Trivadi Ganesan
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
British journal of cancer 2005;93(1):60-9.
2005: Jeremy P Braybrooke; Andrew Slade; Gael Deplanque; Richard Harrop; Srinivasan Madhusudan; Martin D Forster; Rachel Gibson; Andreas Makris; Denis C Talbot; Jan Steiner; Linda White; On Kan; Stuart Naylor; Miles W Carroll; Susan M Kingsman; Adrian L Harris
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1512-20.
2004: Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances R Balkwill; Denis C Talbot; Trivadi Ganesan; Adrian L Harris
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6528-34.
2004: Srinivasan Madhusudan; Gaël Deplanque; Jeremy P Braybrooke; Emma Cattell; Marian Taylor; Pat Price; Marie D Tsaloumas; Niall Moore; Susan M Huson; Chris Adams; Peggy Frith; Paul Scigalla; Adrian L Harris
Antiangiogenic therapy for von Hippel-Lindau disease.
JAMA : the journal of the American Medical Association 2004;291(8):943-4.
2003: Jeremy P Braybrooke; Ji-Liang Li; Leonard Wu; Fiona Caple; Fiona E Benson; Ian D Hickson
Functional interaction between the Bloom's syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D).
The Journal of biological chemistry 2003;278(48):48357-66.
2003: Jeremy P Braybrooke; Nicola C Levitt; Simon P Joel; Theresa Davis; Srinivasan Madhusudan; Helen Turley; Susan Wilner; Adrian L Harris; Denis C Talbot
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4682-8.
2003: Cheng Han; Jeremy P Braybrooke; Gael Deplanque; M Taylor; D Mackintosh; K Kaur; K Samouri; Trivadi Ganesan; Adrian L Harris; Denis C Talbot
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
British journal of cancer 2003;89(7):1166-71.
2003: Jeremy P Braybrooke; M Ranson; C Manegold; K Mattson; N Thatcher; PD Cheverton; M Sekiguchi; M Suzuki; R Oyama; Denis C Talbot
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41(2):215-9.
2003: Jeremy P Braybrooke; Epie Boven; Nicholas Bates; Rita Ruijter; Nicola A Dobbs; PD Cheverton; HERBERT PINEDO; Denis C Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):913-21.
2003: David J Propper; David Chao; Jeremy P Braybrooke; Pru Bahl; Parames Thavasu; Frances R Balkwill; Helen Turley; Nicola A Dobbs; Kevin Gatter; Denis C Talbot; Adrian L Harris; Trivadi Ganesan
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):84-92.
2001: David J Propper; alexander mcdonald; A Man; Parames Thavasu; Frances R Balkwill; Jeremy P Braybrooke; Francesco Caponigro; P Graf; C Dutreix; R Blackie; Stanley B Kaye; Trivadi Ganesan; Denis C Talbot; Adrian L Harris; Chris Twelves
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1485-92.
2000: Jeremy P Braybrooke; KJ O'Byrne; David J Propper; Andrew D Blann; M Saunders; Nicola A Dobbs; C Han; J Woodhull; K Mitchell; Jeremy P Crew; K Smith; R Stephens; Trivadi Ganesan; Denis C Talbot; Adrian L Harris
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4697-704.
2000: Jeremy P Braybrooke; K G Spink; J Thacker; Ian D Hickson
The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2.
The Journal of biological chemistry 2000;275(37):29100-6.
2000: Jeremy P Braybrooke; David J Propper; KJ O'Byrne; MI Koukourakis; Adam Patterson; Sue Houlbrook; S D Love; SM Varcoe; M Taylor; Trivadi Ganesan; Denis C Talbot; Adrian L Harris
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
British journal of cancer 2000;83(2):219-24.
2000: David J Propper; Nicola C Levitt; K O'Byrne; Jeremy P Braybrooke; Denis C Talbot; Trivadi Ganesan; Campbell H Thompson; Bheeshma Rajagopalan; T J Littlewood; Ruth M Dixon; Adrian L Harris
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
British journal of cancer 2000;82(11):1776-82.
2000: David J Propper; Jeremy P Braybrooke; Nicola C Levitt; K O'Byrne; K Christodoulos; C Han; Denis C Talbot; Trivadi Ganesan; Adrian L Harris
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
British journal of cancer 2000;82(11):1759-63.
2000: Jeremy P Braybrooke; K A Vallis; Sue Houlbrook; H Rockett; J Ellmén; Markku Anttila; Trivadi Ganesan; Adrian L Harris; Denis C Talbot
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Cancer chemotherapy and pharmacology 2000;46(1):27-34.
2000: Jeremy P Braybrooke; Sue Houlbrook; J E Crawley; David J Propper; KJ O'Byrne; I J Stratford; Adrian L Harris; D E Shuker; Denis C Talbot
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Cancer chemotherapy and pharmacology 2000;45(2):111-9.
1999: KJ O'Byrne; Philip A Philip; David J Propper; Jeremy P Braybrooke; Mark P Saunders; Nicholas Bates; M A Taylor; D Madigan; Trivadi Ganesan; Denis C Talbot; Adrian L Harris
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):981-3.
1999: David J Propper; Jeremy P Braybrooke; D J Taylor; R Lodi; P Styles; J A Cramer; W C Collins; Nicola C Levitt; Denis C Talbot; Trivadi Ganesan; Adrian L Harris
Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):923-7.
1999: David J Propper; Mark P Saunders; AJ Salisbury; L Long; KJ O'Byrne; Jeremy P Braybrooke; M Dowsett; M Taylor; Denis C Talbot; Trivadi Ganesan; Adrian L Harris
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1682-9.
1999: KJ O'Byrne; Nicola A Dobbs; David J Propper; Jeremy P Braybrooke; MI Koukourakis; K Mitchell; J Woodhull; Denis C Talbot; Andrew V Schally; Adrian L Harris
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
British journal of cancer 1999;79(9-10):1413-8.
1999: VM Macaulay; KJ O'Byrne; Mark P Saunders; Jeremy P Braybrooke; L Long; F Gleeson; C S Mason; Adrian L Harris; P Brown; Denis C Talbot
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):513-20.
1998: David J Propper; VM Macaulay; KJ O'Byrne; Jeremy P Braybrooke; Susan Wilner; Trivadi Ganesan; Denis C Talbot; Adrian L Harris
A phase II study of bryostatin 1 in metastatic malignant melanoma.
British journal of cancer 1998;78(10):1337-41.
1997: Jeremy P Braybrooke; KJ O'Byrne; Mark P Saunders; David J Propper; AJ Salisbury; P Boardman; M Taylor; Trivadi Ganesan; Denis C Talbot; Adrian L Harris
A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(3):294-6.